
BioSpectrum
the business of Bio & Health Sciences
ASIA EDITION

Terason, Anker Biomedical work on diagnosing obstructive sleep apnea

December 20, 2019 | News

AmCADÃ?Â®-UO combines artificial intelligence and advanced signal processing with Terason 's ultrasound imaging technology



Terason, the world's leading ultrasound imaging company headquartered in the US, has partnered with Taiwanbased Anker Biomedical Co., Ltd. (AmCad BioMed Corporation) to provide ultrasound imaging technology for AmCAD®-UO, Anker's innovative obstructive sleep apnea (OSA) solution.

The partnership addresses the market's strong demand for more efficient solutions that help physicians assess the risks of OSA, which affects more than 425 million people worldwide.

AmCAD-UO is the world's first FDA-approved upper respiratory tract assessment solution that uses artificial intelligence (AI) to analyze and reconstruct upper airway ultrasound images taken from conscious patients, using Terason's ultrasound imaging technology Get. This allows doctors to more quickly assess the underlying cause of sleep apnea and to assess patients with moderate / severe OSA.

Dr. Alice Chiang, a pioneer in the industry, founder and CEO of Terason, said: "Our ultrasound imaging technology can be combined with Anker Biotech's AI and advanced signal processing to change the way doctors evaluate and diagnose obstructive sleep apnea. We are very pleased with this method. This intuitive solution takes advantage of the excellent clarity of Terason ultrasound images. Doctors can use this solution to obtain the patient's upper respiratory tract diagnostic information within one hour, which will make the previous inefficient. Process into a simple outpatient procedure. "

The AmCAD-UO solution was welcomed by the industry in the early days of its introduction. The large non-profit medical complex Cleveland University Hospital Medical Center in Cleveland, Ohio was the first to adopt the solution in the United States.

Yi-Li Lee, President of Anker Biomedical said: "We are very optimistic that the deployment of our AmCAD®-UO solution at the University of Cleveland Hospital Medical Center will lay the foundation for widespread industry acceptance and the industry is

seeking a more efficient approach To assess obstructive sleep apnea. Our exclusive technology and partnership with Terason open up endless possibilities for clinical research, predictive surgery success, therapeutic analysis and tracking. "